Trials / Completed
CompletedNCT02094365
A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model
A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Alios Biopharma Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to compare the antiviral effect of ALS-008176 compared to a placebo control in the respiratory syncytial virus challenge model.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALS-008176 | |
| DRUG | vehicle |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2014-06-01
- Completion
- 2014-07-01
- First posted
- 2014-03-21
- Last updated
- 2025-02-03
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02094365. Inclusion in this directory is not an endorsement.